Johnson & Johnson 8-K
NegativeGuidance loweredImpairment / chargeDeal completedContract / partnership
Firefly Bio acquisition and Sail Biomedicines collaboration drive cuts to FY2026 adjusted EPS and operating margin guidance.
Filed 2026-07-29 17:25 ET
- 7.01 Regulation FD Disclosure
- 9.01 Financial Statements and Exhibits
Summary
Firefly Bio acquisition completion and Sail Biomedicines collaboration, with lower FY2026 guidance. J&J paid $1.0B cash for Firefly and entered a collaboration with Sail that includes an exclusive option to acquire it for $2.58B. J&J expects the two transactions to reduce adjusted EPS measures by $0.64 in 2026 and, subject to Sail milestones and exercise of the acquisition option, by $1.36 in 2027.
Key Figures
- Firefly: $1.0B cash acquisition, accounted for as an asset acquisition; an approximately $1.0B in-process research and development charge is expected in Q3 2026.
- Sail: $785M in initial payments, including a $465M equity investment, plus $140M in contingent development-milestone payments. A further $2.58B is payable if J&J exercises its exclusive acquisition option. The transactions are subject to regulatory approvals and/or other conditions.
- Expected adjusted operational EPS and adjusted EPS dilution: $0.64 in 2026 ($0.46 from Firefly and $0.18 from Sail); $1.36 in 2027 ($0.08 from Firefly and $1.28 from Sail). The 2027 Sail impact assumes certain development milestones are achieved and J&J exercises its option.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Adjusted operational sales growth (non-GAAP) | FY2026 | 6.2%-6.8%; midpoint 6.5% | — | Maintained |
| Operational sales (non-GAAP) | FY2026 | $100.3B-$100.9B; midpoint $100.6B; growth 6.5%-7.1%, midpoint 6.8% | — | — |
| Estimated reported sales | FY2026 | $100.8B-$101.4B; midpoint $101.1B; growth 7.0%-7.6%, midpoint 7.3% | — | — |
| Adjusted pre-tax operating margin (non-GAAP) | FY2026 | Decrease ≈75 bp Y/Y | Increase ≈75 bp Y/Y | Lowered; transaction impact ≈150 bp decrease |
| Adjusted operational EPS (non-GAAP) | FY2026 | $10.86-$11.01; midpoint $10.94; growth 0.7%-2.1%, midpoint 1.4% | $11.50-$11.65; midpoint $11.58; growth 6.6%-8.0%, midpoint 7.3% | Lowered; midpoint growth down 5.9 percentage points |
| EPS currency impact | FY2026 | $0.10; 0.9% | — | Maintained |
| Adjusted EPS (non-GAAP) | FY2026 | $10.96-$11.11; midpoint $11.04; growth 1.6%-3.0%, midpoint 2.3% | $11.60-$11.75; midpoint $11.68; growth 7.5%-8.9%, midpoint 8.2% | Lowered; midpoint growth down 5.9 percentage points |
The EPS guidance reductions reflect the expected transaction impacts; J&J did not provide corresponding forward GAAP EPS figures.
Investor Takeaways
- Watch for Sail development milestones and J&J’s decision on whether to exercise the acquisition option; both affect the potential additional payment and the stated 2027 EPS impact.
- Firefly’s research and development progress will determine whether its platform advances toward therapies for difficult-to-treat solid tumors.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3